FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA [Yahoo! Finance]
Ascendis Pharma A/S - American Depositary Shares (ASND)
Last ascendis pharma a/s - american depositary shares earnings: 11/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ascendispharma.com
Company Research
Source: Yahoo! Finance
First-in-class novel PTH replacement therapy Australia becomes the first country to obtain Marketing Authorisation for YORVIPATH since FDA approval SINGAPORE Feb. 20, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) welcomes the registration of YORVIPATH ® (palopegteriparatide) by the Therapeutic Goods Administration (TGA), " for the treatment of chronic hypoparathyroidism in adults" YORVIPATH was granted an Orphan Drug Designation and assessed through the TGA's Priority Review pathway. It is the first and only medicine to be listed on the Australian Register of Therapeutic Goods (ARTG) for the treatment of chronic hypoparathyroidism. (PRNewsfoto/Specialised Therapeutics) Hypoparathyroidism is a rare, complex endocrine disease, affecting an estimated 6.4-37 per 100,000 people globally. It is an endocrine disorder in which the production of parathyroid hormone (PTH) by the parathyroid glands is abnormally low or absent, causing low level
Show less
Read more
Impact Snapshot
Event Time:
ASND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASND alerts
High impacting Ascendis Pharma A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ASND
News
- Here's My Prediction For Who Could Acquire Ascendis Pharma [Seeking Alpha]Seeking Alpha
- Assessing Ascendis Pharma (ASND)'s Valuation After a Strong 69.72% One-Year Shareholder Return [Yahoo! Finance]Yahoo! Finance
- Ascendis Pharma gains amid takeover speculation [Seeking Alpha]Seeking Alpha
- Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by analysts at Stifel Nicolaus from $254.00 to $256.00. They now have a "buy" rating on the stock.MarketBeat
- Former Novo Nordisk Executive Jesper Høiland Joins Alva Therapeutics' Board of DirectorsPR Newswire
ASND
Earnings
- 11/12/25 - Miss
ASND
Sec Filings
- 12/10/25 - Form 6-K
- 12/4/25 - Form 144
- 12/2/25 - Form 144
- ASND's page on the SEC website